Abstract
Introduction A subgroup of anti-platelet factor 4 (PF4) antibodies can activate platelets via Fcgamma RIIA and cause thrombotic and thrombocytopenic diseases such as heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia (VITT). Nonpathological anti-PF4 antibodies are detected in 1-7% of healthy blood donors and in 2-8% of SARS-CoV-2 vaccinated individuals. In this study, we investigated the long-term course of anti-PF4 antibodies detected after the first SARS-CoV-2 vaccination in healthy subjects and in patients with VITT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
